SCHEMBL4474072

SCHEMBL4474072

NCc1cncc(Cl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.48
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
AOC1 P19801 5/20 0.35
AOC3 Q16853 5/20 0.35
DPP4 P27487 2/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
GAA P10253 1/20 0.33
CDK2 P24941 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22764089 0.76 GRK2 (0.33)
SCHEMBL4487443 0.76 PDXK (0.36)
SCHEMBL337576 0.73
SCHEMBL5013390 0.72 AOC3 (0.43) PNMTGABRA1GABRB2AOC1AOC3
Hydrochloric Acid SCHEMBL5010440 0.70 AOC3 (0.46) PNMTGABRA1GABRB2AOC1AOC3
SCHEMBL4347118 0.70
SCHEMBL3291159 0.70
Hydrochloric Acid SCHEMBL22189785 0.68 AOC1 (0.61) PNMTAOC1AOC3LOXL2GAA
SCHEMBL30905964 0.67
SCHEMBL23374478 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601714-B2 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-20080287410-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BARBOSA ANTONIO J M 2008-11-20 US disclosed
EP-1765791-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-03-28 EP disclosed
WO-2006014482-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-09 WO disclosed
US-20060025433-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287410-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA PRKCZ, PRKCQ, PRKCH PNMT 1339/4885GABRA1 3160/4885GABRB2 2193/4885
US-20060025433-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta PRKCZ, PRKCQ, PRKCH PNMT 1339/4885GABRA1 3160/4885GABRB2 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.